Investigation of main indicators for implementing a regional preferential drug provision program for the population of the Samara Region


I.K. Petrukhina(1), R.I. Yagudina(2), T.K. Ryazanova(1), G.A. Egorova(1), A.A. Bubnova(1), L.V. Loginova(1) 1-Samara State Medical University, 89, Chapaevskaya St., Samara 443099, Russian Federation; 2-I.M. Sechenov First Moscow State Medical University (Sechenov University), 8, Trubetskaya St., Build. 2, Moscow 119991, Russia

Introduction. Preferential drug provision programs had a significant impact on the development of the pharmaceutical market. They are a measure of social support for citizens of all age groups, who live in different subjects of the Russian Federation. The public authorities of the subjects of the Russian Federation have authority to organize the provision of certain categories of citizens with essential medicines (regional preferential drug provision programs (RPDPP)). An analysis of the indicators of RPDPP implementation for a number of years makes it possible to comparatively investigate the cost structure of drugs and to scientifically substantiate approaches to rationally spending the budget funds, to creating the program budget, and to predicting the future demand for medicines. Objective: to investigate the features of drug use by beneficiaries of regional responsibility as part of RPDPP implementation in case of the Samara Region. Materials and methods. The investigation object was data on the nomenclature of drugs dispensed to the population of the Samara Region as part of RPDPP implementation in the period 2014 to 2018. The investigators analyzed the structure of a drug assortment according to the amount of financial costs; the price characteristics of groups in accordance with the anatomical therapeutic chemical (ATC) classification; and the scope of using the prescribed drugs in natural and monetary terms. The investigation used techniques for comparative, retrospective, logical, graphical, and content analyses and a method for data grouping according to the ATC classification. Results. By using the Samara Region as an example, the investigators carried out a comparative analysis of the changes in the main RPDPP implementation indicators (funding amounts for the implementation of the program; the actual average drug acquisition cost per applying beneficiary; the average cost of one prescription; the structure of costs depending on the category of beneficiaries, etc.), which had occurred in 2014-2018. It was established that more than 50% of the RPDPP budget allocated for the purchase of drugs is spent on drugs that affected the digestive tract and metabolism (mainly drugs for the treatment of diabetes mellitus), antineoplastic agents, and immunomodulators. Synthetic antidiabetic medications, as well as antiasthmatic drugs constituted a significant portion of the consumption structure in natural terms within the RPDPP. Conclusion. The analysis of changes in the main indicators of implementing RPDPP in the Samara Region over 2014–2018 identified the most costly categories of diseases for the RPDPP budget. The results of this analysis can be used as the basis for the development of methodological recommendations for the rational spending of budgetary funds, the creation of the program budget, and the prediction of future demand for drugs.

preferential drug provision
drug provision for regional beneficiaries
regional preferential drug provision program
assortment of drugs
ATC classification
costs of drugs by nosological entities

  1. Vorobev P.A., Bezmelnitsyna L.Yu. Organization of drug provision in the Russian Federation. Problemy standartizatsii v zdravookhranenii. 2013; 3–4: 3–8 (in Russian)
  2. Order of the Ministry of Health of Russia dated February 13, 2013. №66 (as amended on 04/07/2016) «On approval of the Strategy for drug provision of the population of the Russian Federation for the period until 2025 and a plan for its implementation» (in Russian)
  3. Yurgel' N.V., Tel'nova Е.А. The state of the pharmaceutical market of the Russian Federation and the impact on it of the global financial and economic crisis. Vestnik Roszdravnadzora. 2015; 1: 4 (in Russian)
  4. Petrukhina I.K., Kurkin V.А. Analysis of the implementation of drug support programs for regional beneficiaries. Sibirskiy meditsinskiy zhurnal. 2015; 134 (3): 81–4 (in Russian)
  5. Procurement of regional preferential drug supply programs. Remedium. 2015; 13: 78–9 (in Russian)
  6. Os'kina Е.A., Polubentseva Е.I., Kuznetsov S.I., Sirotko I.I. Improving the organization of preferential drug provision in the Samara region using AIS. Meditsinskiye tekhnologii. Otsenka i vybor. 2011; 1: 63–6 (in Russian)
  7. Petrukhina I.K. Analysis of the implementation of the program of preferential drug provision for the population in the Volga Federal District. Aspirantskiy vestnik Povolzh'ya. 2014; 1–2: 225–8 (in Russian)
  8. Analytical review «The pharmaceutical market of Russia. 2017 Results». DSM Group, 2019. [Electronic resource]. Access mode:: URL: (in Russian)
  9. Yurgel' N.V. The history of the issue of preferential drug provision. Remedium. 2009; 3: 22 (in Russian)